Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUROPA: Exclusive Endocrine Therapy or Radiation Therapy for Women Aged ≥70 Years With Luminal A-like Early Stage Breast Cancer
NCT04134598Phase 3Active, not recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- Feb 2021
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Azienda Ospedaliero-Universitaria Careggi. Primary endpoints: Health-Related Quality of Life assessed by EORTC QLQ-C30 at 24 months and Time to ipsilateral breast tumor recurrence at 60 months. Started Feb 2021; status: active, not recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04134598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134598.